Patent-litigation settlement agreements struck between Servier and four generics firms – Lupin, Mylan, Teva and Unichem – that delayed generic market entry on perindopril in exchange for financial benefits “constitute restrictions of competition by object”, according to the European Union’s (EU’s) General Court. The finding upholds in part a European Commission decision from 2014 in which the Commission found that Servier had implemented an “exclusionary strategy” on perindopril.
However, as part of the General Court’s ruling, it has reduced the Commission’s €331 million (US$377 million) fine imposed on...
